(elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024 CHMP positive opinion for
GENFIT: Ipsen's Iqirvo (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA
On J, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC). Type: Small
In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor. In June 2024, the US FDA granted accelerated approval to
Approval FDA Grants Accelerated Approval to Iqirvo (elafibranor) for the Treatment of Primary Biliary Cholangitis: : Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease, PBC:
This month, the FDA granted accelerated approval to Iqirvo (elafibranor) for the treatment of an autoimmune disease that can affect the
The U.S. FDA has granted accelerated approval to Iqirvo (elafibranor) for the treatment of primary biliary cholangitis in combination with
FDA Accelerated Approval. GENFIT: Ipsen's Iqirvo (Elafibranor) Receives EU Approval FDA Accelerated Approval. Plus d'actualités Cotations et
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!
Do you realize the world doesn't end at USA borders?